African pharmaceutical manufacture myth or reality presentation

Source: GIZ (2011) EAC pharmaceutical manufacturing survey

Why the increased interest in African Pharma?

Estimated IFC (2009)~US$3.8 billion by 2016, others forecast US$ 23 billion by 2020

Local manufacturers account for Only 25–30%

Population Current: 1.033 billion

Estimated: 1.3 billion by 2020

http://www.strategyand.pwc.com/media/file/Strategyand_Pharma-Emerging-Markets-2.0.pdf

Increasingly there is purposive engagement to influence policy.

However power and influence over policy and direction:

Global Health Players/Institutions » Continental » Regional »Local institutions!!!

R&D; Reformulation

Global Health Systems

Local Health Sytem Financing

Procurement as an Asset: Mackintosh and Chataway (2013) – Personal Communication

Reductions and Increase

Country 2001 2011 Mozambique 14.8% 7.8%

Chad 13.8% 3.3%

DRC 2.8% 10.8%

Achievers

Country 2011 Rwanda 23.8%

Liberia 18.9%

Malawi 18.5%

Zambia 16.0%

Togo 15.4%

Madagascar 15.3%

Nearly There…….

Country 2011 Swaziland 14.9%

Ethiopia 14.6%

Lesotho 14.6%

Djibouti 14.2%

https://www.devex.com/news/health-funding-in-africa-how-close-is-the-au-to-meeting-abuja-targets-81567 accessed 22/04/2014

MNCs see African pharmaceutical markets as a long

term opportunity because of lack of assured public

health financing

If public health funding is resolved then local

manufacturers will face intense competition from

mature market players seeking new avenues for

revenue and profit growth

Source: Banda (2013). Finance as a forgotten technological capability for promoting African local pharmaceutical

manufacture in Africa. International Journal of Technology Management and Sustainable Development. 12 (2)

Source: Banda (2013). Finance as a forgotten technological capability for promoting African local pharmaceutical

manufacture in Africa. International Journal of Technology Management and Sustainable Development. 12 (2)